These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 2258780)

  • 1. Analysis of time trends, individual subject responses and background variation in crossover factorial studies with antihypertensive drugs.
    Chalmers J; Wing L; Taylor S
    J Hypertens Suppl; 1990 Sep; 8(4):S27-35. PubMed ID: 2258780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Losartan with hydrochlorothiazide in the treatment of hypertension.
    Schoenberger JA;
    J Hypertens Suppl; 1995 Jul; 13(1):S43-7. PubMed ID: 18800455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factorial antihypertensive study of an extended-release metoprolol and hydrochlorothiazide combination.
    Papademetriou V; Hainer JW; Sugg J; Munzer D;
    Am J Hypertens; 2006 Dec; 19(12):1217-25. PubMed ID: 17161766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response curves in antihypertensive combination therapy: results of a controlled clinical trial.
    Letzel H; Bluemner E
    J Hypertens Suppl; 1990 Sep; 8(4):S83-6. PubMed ID: 2258790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hypertension with enalapril and hydrochlorothiazide or enalapril and atenolol: contrasts in hypotensive interactions.
    Wing LM; Chalmers JP; West MJ; Bune AJ; Russell AE; Elliott JM; Morris MJ
    J Hypertens Suppl; 1987 Dec; 5(5):S603-6. PubMed ID: 2832575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enalapril as a first-step agent in essential hypertension: a comparative study with atenolol.
    Edmonds D; Greminger P; Locher R; Knorr M; Vetter H; Vetter W
    J Hypertens Suppl; 1986 Dec; 4(5):S406-9. PubMed ID: 3033180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study.
    Suonsyrjä T; Hannila-Handelberg T; Paavonen KJ; Miettinen HE; Donner K; Strandberg T; Tikkanen I; Tilvis R; Pentikäinen PJ; Kontula K; Hiltunen TP
    J Hypertens; 2008 Jun; 26(6):1250-6. PubMed ID: 18475165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
    Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
    J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies.
    Naidoo DP; Sareli P; Marin F; Aroca-Martinez G; Maritz FJ; Jardim PC; Guerrero AA; Thompson CA; Bero T; Drazka J; Kosmalova V; Dumortier T; Smith RD
    Adv Ther; 1999; 16(5):187-99. PubMed ID: 10915394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An equivalence study of the safety and efficacy of a fixed-dose combination of perindopril with indapamide versus fixed-dose combinations of captopril with hydrochlorothiazide and enalapril with hydrochlorothiazide in the treatment of hypertension.
    Luccioni R; Sever PS; Di Perri T; Redon J; Laurandin I; Brault Y; Chastang C; Guez D
    J Hypertens; 1995 Dec; 13(12 Pt 2):1847-51. PubMed ID: 8903665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.
    MacKay JH; Arcuri KE; Goldberg AI; Snapinn SM; Sweet CS
    Arch Intern Med; 1996 Feb; 156(3):278-85. PubMed ID: 8572837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients.
    de la Sierra A; Gil-Extremera B; Calvo C; Campo C; García-Puig J; Márquez E; Oliván J; Roca Cusachs A; Sanz de Castro S; Pontes C; Delgadillo J
    J Hum Hypertens; 2004 Mar; 18(3):215-22. PubMed ID: 14973517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction.
    Wald DS; Law M; Mills S; Bestwick JP; Morris JK; Wald NJ
    Clin Ther; 2008 Nov; 30(11):2030-9. PubMed ID: 19108791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enalapril, hydrochlorothiazide, and combination therapy in patients with moderate hypertension.
    Frishman WH; Goldberger J; Sherman D
    J Clin Hypertens; 1987 Dec; 3(4):520-7. PubMed ID: 2839628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of crossover trials to obtain antihypertensive dose-response curves and to study combination therapy during the development of benazepril.
    Bellet M; Whalen JJ; Bodin F; Serrurier D; Tanner K; Ménard J
    J Hypertens Suppl; 1990 Sep; 8(4):S43-8. PubMed ID: 2258783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide.
    Frishman WH; Bryzinski BS; Coulson LR; DeQuattro VL; Vlachakis ND; Mroczek WJ; Dukart G; Goldberg JD; Alemayehu D; Koury K
    Arch Intern Med; 1994 Jul; 154(13):1461-8. PubMed ID: 8018001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.